Physician profile
Steve Perkins
NPI 1790780500
$3,987.56
in general payments reported to CMS, 2019-2025
32 companies · $1,852 in 2025
The $1,852 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $13.84 · 2021: $383 · 2022: $145 · 2023: $53.75 · 2024: $1,423 · 2025: $1,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,180 · Food and Beverage: $965 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,179.99 |
| Food and Beverage | $964.72 |
| Education | $184.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,295.54 | 2022-2025 | |
| Janssen Biotech, INC. | $208.66 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Regeneron Healthcare Solutions, INC. | $141.87 | 2022-2024 | Libtayo |
| Myriad Genetic Laboratories, INC. | $121.55 | 2021 | |
| Celgene Corporation | $119.90 | 2019-2025 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $109.18 | 2021 | |
| Lilly USA, LLC | $100.36 | 2021 | |
| Abbvie INC. | $99.98 | 2019-2025 | |
| Array Biopharma INC | $80.45 | 2025 | Xalkori, Braftovi, Mektovi |
| Apellis Pharmaceuticals, INC. | $68.15 | 2023-2024 | Empaveli |
| E.R. Squibb & Sons, L.L.C. | $58.65 | 2025 | Opdivo |
| Daiichi Sankyo INC. | $55.48 | 2023-2025 | Enhertu, Datroway |
| Incyte Corporation | $52.73 | 2025 | Jakafi, Monjuvi |
| Geron Corporation | $50.10 | 2025 | Rytelo |
| Merck Sharp & Dohme LLC | $42.70 | 2019-2024 | Keytruda |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $40.00 | 2021 | |
| Pfizer INC. | $35.74 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.77 | 2025 | Iclusig |
| Sobi, INC | $28.12 | 2025 | |
| Gilead Sciences, INC. | $27.73 | 2021-2025 | Trodelvy |
| Myovant Sciences INC. | $25.74 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $24.90 | 2022 | |
| Janssen Scientific Affairs, LLC | $21.20 | 2025 | Tecvayli, Talvey, Darzalex |
| Kite Pharma, INC. | $21.16 | 2025 | Yescarta |
| Coherus Oncology, INC. | $20.59 | 2025 | Loqtorzi |
| Bayer Healthcare Pharmaceuticals INC. | $20.28 | 2025 | |
| Karyopharm Therapeutics INC. | $15.76 | 2024 | Xpovio |
| Amgen INC. | $15.01 | 2022 | |
| Beigene USA, INC. | $14.88 | 2025 | Tevimbra |
| Verastem, INC. | $13.84 | 2020 | |
| Seagen INC. | $13.29 | 2022 | |
| Pharmaessentia USA Corporation | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.